Pierre Gholam MD
@livermd.bsky.social
Hepatologist at University Hospitals of Cleveland and Professor at Case Western Reserve University SOM. Interested in liver cancer and all things #liversky
Husband, dad, wannabe world traveler and procrastinator.
Husband, dad, wannabe world traveler and procrastinator.
Many patients had been on Ocaliva for years with a good response and tolerability.
Since 2016, intercept invested a significant amount of time, effort and resources towards elevating patient voices, raising awareness and bridging the knowledge gap.
Let’s at least give them credit for this.
Since 2016, intercept invested a significant amount of time, effort and resources towards elevating patient voices, raising awareness and bridging the knowledge gap.
Let’s at least give them credit for this.
September 11, 2025 at 7:35 PM
Many patients had been on Ocaliva for years with a good response and tolerability.
Since 2016, intercept invested a significant amount of time, effort and resources towards elevating patient voices, raising awareness and bridging the knowledge gap.
Let’s at least give them credit for this.
Since 2016, intercept invested a significant amount of time, effort and resources towards elevating patient voices, raising awareness and bridging the knowledge gap.
Let’s at least give them credit for this.
The evidence presented by regulators leaves me unconvinced that presumed OCA hepatotoxicity is a systemic and pervasive issue that requires decisive action.
Fortunately, we now have other better tolerated drugs that are effective in second line for persons living with PBC.
Fortunately, we now have other better tolerated drugs that are effective in second line for persons living with PBC.
September 11, 2025 at 7:32 PM
The evidence presented by regulators leaves me unconvinced that presumed OCA hepatotoxicity is a systemic and pervasive issue that requires decisive action.
Fortunately, we now have other better tolerated drugs that are effective in second line for persons living with PBC.
Fortunately, we now have other better tolerated drugs that are effective in second line for persons living with PBC.
Having options in the management of a complex disease with multiple nutritional, metabolic, environmental & genetic inputs is important.
There are potential synergies between drugs with different mechanisms of action (MOA). I anticipate at least 5 more approvals with novel MOAs in the coming 5 y
There are potential synergies between drugs with different mechanisms of action (MOA). I anticipate at least 5 more approvals with novel MOAs in the coming 5 y
August 16, 2025 at 7:03 PM
Having options in the management of a complex disease with multiple nutritional, metabolic, environmental & genetic inputs is important.
There are potential synergies between drugs with different mechanisms of action (MOA). I anticipate at least 5 more approvals with novel MOAs in the coming 5 y
There are potential synergies between drugs with different mechanisms of action (MOA). I anticipate at least 5 more approvals with novel MOAs in the coming 5 y
Having options in the management of a complex disease with multiple nutritional, metabolic, environmental & genetic inputs is important.
A real question that will be answered soon is how will payers react?
#semaglutide now has 5 approved indications. Payers reliably only cover one.
#liversky
A real question that will be answered soon is how will payers react?
#semaglutide now has 5 approved indications. Payers reliably only cover one.
#liversky
August 16, 2025 at 6:53 PM
Having options in the management of a complex disease with multiple nutritional, metabolic, environmental & genetic inputs is important.
A real question that will be answered soon is how will payers react?
#semaglutide now has 5 approved indications. Payers reliably only cover one.
#liversky
A real question that will be answered soon is how will payers react?
#semaglutide now has 5 approved indications. Payers reliably only cover one.
#liversky